Tectonic Therapeutic, Inc. TECX
Tectonic Therapeutic, Inc. (Nasdaq: TECX) is a cardio-renal-metabolic drug developer. Its lead program, TX45, is in Phase 2 for Group 2 pulmonary hypertension in HFpEF (PH-HFpEF). Its next catalyst on record is TX45 APEX: Topline results (Q1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: TX45 APEX — Topline results (Q1 2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| TX45 (Fc-relaxin fusion) APEX | PH-HFpEF | protein/peptide | Phase 2 |
| TX45 open-label Phase 2 | PH-ILD (Group 3 PH) | protein/peptide | Phase 2 |
| TX2100 (anti-APJ VHH-Fc antagonist) | hereditary hemorrhagic telangiectasia (HHT) | antibody | Phase 1 |
Recent results and decisions
- Sep 29, 2026positive TX2100 Phase 1a SAD trial in 48 healthy volunteers met primary objectives: generally safe and well tolerated, no deaths, SAEs or severe TEAEs at any dose.
There were no deaths, serious adverse events (SAEs) or severe TEAEs at any dose.
Filing - Sep 29, 2026n/a FDA granted Fast Track designation for TX2100 in HHT and cleared the IND for the Phase 1b trial (Aug 2026).
The Company also announced that the U.S. Food and Drug Administration (FDA) granted TX2100 Fast Track Designation for HHT.
Filing - Aug 6, 2026completed enrollment Completed enrollment of 191 patients (137 with CpcPH and PVR>3 WU) in the TX45 APEX Phase 2 trial in June 2026; IDMC recommended continuing without modification.
In June 2026, the Company completed enrollment for the APEX trial, a global, randomized, placebo-controlled 24-week Phase 2 clinical trial evaluating the safety and efficacy of TX45 in patients with PH-HFpEF.
Filing
2 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.